Treatment of Neuromyelitis Optica: Review and Recommendations. (Q37588037)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24555176%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

title

Treatment of Neuromyelitis Optica: Review and Recommendations (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24555176%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24555176%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Ichiro Nakashima

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24555176%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Anthony Traboulsee

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24555176%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

9

Jacqueline Palace

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24555176%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

15

Brian G Weinshenker

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24555176%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

author name string

Kazuo Fujihara

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24555176%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Anu Jacob

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24555176%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Marco A Lana-Peixoto

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24555176%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Maria Isabel Leite

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24555176%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Michael Levy

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24555176%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Romain Marignier

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24555176%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Jérôme de Seze

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24555176%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Olaf Stuve

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24555176%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Silvia N Tenembaum

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24555176%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Dean M Wingerchuk

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24555176%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

GJCF-CC&BR

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24555176%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Emmanuelle Waubant

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24555176%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

publication date

1 October 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24555176%20AND%20SRC:MED&resulttype=core&format=json

Multiple Sclerosis and Related Disorders

8 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24555176%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

volume

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24555176%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24555176%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

page(s)

180-187

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24555176%20AND%20SRC:MED&resulttype=core&format=json

Neutrophil protease inhibition reduces neuromyelitis optica-immunoglobulin G-induced damage in mouse brain

8 March 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926208

Protective effect of an elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin oligodendroglial glycoprotein

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926208

Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926208

Neuromyelitis optica treatment: analysis of 36 patients

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926208

Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926208

Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926208

Traditional concepts and future avenues of glucocorticoid action in experimental autoimmune encephalomyelitis and multiple sclerosis therapy

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926208

Antibody to aquaporin-4 in the long-term course of neuromyelitis optica

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926208

Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926208

Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926208

CNS aquaporin-4 autoimmunity in children

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926208

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926208

Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926208

Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease).

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926208

Revised diagnostic criteria for neuromyelitis optica

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926208

IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926208

Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926208

A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926208

Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926208

A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926208

Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926208

Integrative continuum: accelerating therapeutic advances in rare autoimmune diseases

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926208

Treatment of neuromyelitis optica: an evidence based review

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926208

Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926208

IFNβ-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926208

Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926208

Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926208

Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926208

Progressive multifocal leukoencephalopathy and use of mycophenolate mofetil after kidney transplantation

25 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926208

Failure of natalizumab to prevent relapses in neuromyelitis optica.

25 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926208

Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926208

PML and rheumatology: the contribution of disease and drugs

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926208

Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926208

Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926208

Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926208

Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926208

Relapsing neuromyelitis optica: demographic and clinical features in Iranian patients.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926208

Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926208

Intermittent intravenous immunoglobulin successfully prevents relapses of neuromyelitis optica.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926208

Immunosuppressive therapy is more effective than interferon in neuromyelitis optica.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926208

Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926208

Sustained improvement of a girl affected with Devic's disease over 2 years of mycophenolate mofetil treatment.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926208

An open label study of the effects of rituximab in neuromyelitis optica

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926208

Devic's neuromyelitis optica treated with intravenous gamma globulin (IVIG).

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926208

Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926208

Different responses to interferon beta-1b treatment in patients with neuromyelitis optica and multiple sclerosis

3 December 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3926208

The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial

3 December 2018

1 reference

12 December 2020

A secondary progressive clinical course is uncommon in neuromyelitis optica

1 reference

12 December 2020

White matter disease: optimizing rituximab therapy for neuromyelitis optica

1 reference

12 December 2020

Idiopathic transverse myelitis: corticosteroids, plasma exchange, or cyclophosphamide

1 reference

12 December 2020

Anti-aquaporin-4 antibody induces astrocytic cytotoxicity in the absence of CNS antigen-specific T cells

1 reference

12 December 2020

Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab

1 reference

12 December 2020

Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine

1 reference

12 December 2020

Impact of rituximab on relapse rate and disability in neuromyelitis optica

1 reference

12 December 2020

Pharmacoeconomic analyses of azathioprine, methotrexate and prospective pharmacogenetic testing for the management of inflammatory bowel disease

1 reference

12 December 2020

10.1016/J.MSARD.2012.06.002

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24555176%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24555176%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24555176%20AND%20SRC:MED&resulttype=core&format=json